In addition to CD4 T cells, therapeutic protein vaccine treatment highly enhanced CD8 T cell tumor infiltration and improved their TCR avidity and functionality—an effect further enhanced by combination with STINGa—while simultaneously increasing the expression of exhaustion markers PD-1 and Tim-3. Here, CD8A is linked to neoplasm.